- SRT 1720
-
- $31.00 / 2mg
-
2025-12-22
- CAS:925434-55-5
- Min. Order:
- Purity: 99.70%
- Supply Ability: 10g
|
| | N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide Basic information |
| Product Name: | N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide | | Synonyms: | N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide;N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide;2-QuinoxalinecarboxaMide, N-[2-[3-(1-piperazinylMethyl)iMidazo[2,1-b]thiazol-6-yl]phenyl]-;Quinoxaline-2-carboxylic acid [2-(3-piperazin-1-ylmethyl-imidazo[2,1-b]thiazol-6-yl)-phenyl]-amide;SRT1720 free base/ STR1720 HCl salt;SRT1720 - CAS 925434-55-5 - Calbiochem;N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide;SRT 1720, 10 mM in DMSO | | CAS: | 925434-55-5 | | MF: | C25H23N7OS | | MW: | 469.56 | | EINECS: | | | Product Categories: | | | Mol File: | 925434-55-5.mol | ![N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide Structure](CAS/GIF/925434-55-5.gif) |
| | N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide Chemical Properties |
| Melting point | 221℃ | | density | 1.46 | | storage temp. | -20C | | solubility | DMSO:5.0(Max Conc. mg/mL);10.65(Max Conc. mM) | | form | Yellow solid | | pka | 11.19±0.70(Predicted) | | color | Light yellow to yellow |
| | N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide Usage And Synthesis |
| Uses | SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively. | | General Description | A cell-permeable quinolinecarboxamide compound that is shown to inhibit the mitochondrial SIRT3 in a substrate AceCS2-competitive (Ki = 0.56 μM; Km = 2.44 μM), but NAD+-uncompetitive (Ki = 0.34 μM; Km = 280 μM), manner. Also reported to decrease cellular p53 Lys382 acetylation (Effective conc. = 10 μM in U2OS and MEF cultures) and inhibit p300 HAT activity (IC50 = 9 μM) in vitro, as well as offer therapeutic benefits in several murine and rodent type 2 diabetes models (100 mg/kg/dayl p.o.) in vivo. Whether and how SRT1720 activates SIRT1 activity remains uncertain. Also available as a 25 mM solution in DMSO (Cat. No. 530748). | | in vivo | SRT 1720 (10, 30, 100 mg/kg, p.o.) significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing elevated insulin levels similar to rosiglitazone treatment. SRT 1720 treatment significantly reduces fasting blood glucose to near normal levels in Lepob/ob mice[1]. SRT 1720 has ability to protect against the negative effects of diet-induced obesity in mice, and has a connection to metabolic adaptation in fatty acid and oxidative metabolism through downstream targets of SIRT1 such as PGC1α and FOXO1[2]. SRT 1720 (50-100 mg/kg, p.o.), during emphysema development attenuates elastase-induced airspace enlargement and lung function impairment as well as reduces arterial oxygen saturation in WT mice[3]. | | IC 50 | SIRT1: 0.16 μM (EC1.5); SIRT2: 37 μM (EC1.5) | | storage | Store at -20°C | | References | [1] Milne JC et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450(7170):712-6 DOI:10.1038/nature06261
[2] Baur JA, et al. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov. 2012 Jun 1;11(6):443-61 DOI:10.1038/nrd3738
[3] Yao H, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J Clin Invest. 2012 Jun 1;122(6):2032-45. DOI:10.1172/JCI60132
[4] Yu L, et al. Protective effects of SRT1720 via the HNF1α/FXR signalling pathway and anti-inflammatory mechanisms in mice with estrogen-induced cholestatic liver injury. Toxicol Lett. 2016 Dec 15;264:1-11. DOI:10.1016/j.toxlet.2016.10.016 |
| | N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide Preparation Products And Raw materials |
|